Tagrisso leads other drugs in first-line lung cancer survival

AstraZeneca has improved the total lifetime (OS) required to treat tagrisso for lung cancer as it tries to double its use in first-line treatment environments.

results from the FLAURA trial show that Tagrisso extended the survival of previously untreated EGFR-positive non-small cell lung cancer (NSCLC) patients, based on 2017 results showing that the drug can extend progress-free survival (PFS).
According to AstraZenecom's head of oncology, Jose Baselga, the improvement in survival rates exceeds that of other drugs in the EGFR inhibitor category, namely AstraZeneta's own Ereshaer (Gifetini) and Roche's Trotinib, which are the only drugs that can achieve this result.
"Tagrisso provides unprecedented survival results in non-small cell lung cancer with first-line EGFR mutations compared to previous standard care EGFR inhibitors," he said, meaning it should be the new standard treatment for this adaptive disorder. "
the operating system Tagrisso in FLAURA showed an improved trend before the test, but the early readings were too immature to show statistically significant benefits.
Now, the new data should help AstraZeneta continue to build momentum with Tagrisso, as new players such as Pfizer's Vizimpro compete for market share as competition in the EGFR inhibitor category grows.
It will also help the company state its reasons to the payer. AstraZeneta, for example, is appealing a decision by NIC, the UK's cost-benefit agency, to reject Tagrisso's first-line EGFR-positive NSCLC treatment, in part because survival figures are inconclusive compared with older, cheaper rivals.
NICE also determined that the drug did not qualify for inclusion in the Cancer Drugs Fund, saying it was too expensive, and it recommended Pfizer's Vizimpro for routine NHS treatment for the condition.
Tagrisso already dominates the second-tier egfr-positive non-small cell lung cancer market, and AstraZeneta has been trying to push new drugs to the front line, which appears to have had some success in many markets.
In its first-half results, AstraZeneta reported that sales at tagrisso nearly doubled to $1.4bn, driven by first-line drugs from the US, Europe and Japan and second-tier drugs from China. At current growth rates, The drug could reach $3 billion this year, According to AstraZenecom. （cyy123.com）